<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641133</url>
  </required_header>
  <id_info>
    <org_study_id>115992</org_study_id>
    <nct_id>NCT01641133</nct_id>
  </id_info>
  <brief_title>Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™</brief_title>
  <official_title>Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The primary aim of this study is to assess the reactogenicity of Synflorix™ vaccine and
      Prevenar 13™ vaccine after primary vaccination at 2 and 4 months of age with either
      Synflorix™ or Prevenar 13™ vaccine or Prevenar 13™ and Synflorix™, respectively. In addition,
      this study aims at assessing the safety, reactogenicity, immunogenicity and antibody
      persistence (approximately 8-11 months following primary vaccination) of the Synflorix™
      vaccine and Prevenar 13™ vaccine after primary vaccination at 2 and 4 months of age with
      either Synflorix™ or Prevenar 13™ vaccine or Prevenar 13™ and Synflorix™, respectively. This
      study also aims at assessing the safety, reactogenicity and immunogenicity of the Synflorix™
      vaccine when given as a booster dose at 12-15 months of age following primary vaccination at
      2 and 4 months of age with either Synflorix™ vaccine or Prevenar 13™ vaccine or Prevenar 13™
      and Synflorix™, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is partially blinded as the primary phase will be conducted in an observer-blind
      method and booster phase will be open method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited)</measure>
    <time_frame>Within 31-day (Day 0-Day 30) after any dose of primary vaccination</time_frame>
    <description>The number of subjects with Grade 3 AEs (solicited and unsolicited), during the 31-day post-vaccination period following each primary dose is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-vaccination period following each primary dose</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-booster vaccination period</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-vaccination period following each primary dose</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 4-day (Days 0-3) post-booster vaccination period</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Symptoms (Solicited and Unsolicited)</measure>
    <time_frame>During the 31-day (Days 0-30) post-booster vaccination period</time_frame>
    <description>The number of subjects with any and grade 3 symptoms (solicited and unsolicited), during the 31-day post-booster vaccination period is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs</measure>
    <time_frame>During the 31-day (Days 0-30) post-primary vaccination period</time_frame>
    <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs</measure>
    <time_frame>During the 31-day (Days 0-30) post-booster vaccination period</time_frame>
    <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From first vaccination (Month 0) up to study end (11-14 months)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Serotypes</measure>
    <time_frame>At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)</time_frame>
    <description>Antibodies assessed for this outcome measure were those against the vaccine/cross-reactive pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (ANTI-1, -3, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F). Antibody concentrations were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Antibodies Against Protein D (Anti-PD)</measure>
    <time_frame>At study Month 3 (one month after primary vaccination) and at study Month 11 (one month after booster vaccination)</time_frame>
    <description>Anti-PD antibody concentrations were measured by Enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL). The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 153 EL.U/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">457</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Synflorix™ at Month 0, Month 2 and Month 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Prevenar 13™ at Month 0 and Synflorix™ at Month 2 and Month 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Prevenar 13 ™ at Month 0 and Month 2 and Synflorix™ at Month10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix™ (3-Dose)</intervention_name>
    <description>3 doses administered intramuscularly</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix™ (2-Dose)</intervention_name>
    <description>2 doses administered intramuscularly</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix™ (Single Dose)</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13 ™ (Single Dose)</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13 ™ (2-Dose)</intervention_name>
    <description>2 doses administered intramuscularly</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that parent(s)/Legally Acceptable
             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.

          -  A male or female between, and including, 6-12 weeks of age at the time of the first
             vaccination.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Born after a gestation period of at least 36 weeks.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccines, or planned use during the
             entire study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth or planned use during the study.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the study vaccine.

          -  Major congenital defects or serious chronic illness.

          -  History of any seizures or progressive neurological disease.

          -  Administration of immunoglobulins and/or blood products since birth or planned use
             during the study.

          -  Acute disease and/or fever at the time of enrolment.

          -  Previous vaccination or planned vaccination during the study with any pneumococcal
             vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>January 9, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <disposition_first_submitted>August 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2013</disposition_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumococcal conjugate vaccine</keyword>
  <keyword>Synflorix™</keyword>
  <keyword>Prevenar 13™</keyword>
  <keyword>Pneumococcal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>457 subjects were enrolled in the study. Of these, 5 subjects were not included in the Total Vaccinated Cohort, as the study vaccine was not administered. In addition, 157 subjects enrolled at one center were excluded from analysis because of GCP deficiencies, and 1 subject from another center because of invalid Informed Consent form.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Group</title>
          <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Prevnar 1 Group</title>
          <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Prevnar 2 Group</title>
          <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Group</title>
          <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Prevnar 1 Group</title>
          <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Prevnar 2 Group</title>
          <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="98"/>
            <count group_id="B4" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="1.3"/>
                    <measurement group_id="B2" value="7.4" spread="1.5"/>
                    <measurement group_id="B3" value="7.4" spread="1.6"/>
                    <measurement group_id="B4" value="7.4" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited)</title>
        <description>The number of subjects with Grade 3 AEs (solicited and unsolicited), during the 31-day post-vaccination period following each primary dose is reported.</description>
        <time_frame>Within 31-day (Day 0-Day 30) after any dose of primary vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited)</title>
          <description>The number of subjects with Grade 3 AEs (solicited and unsolicited), during the 31-day post-vaccination period following each primary dose is reported.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General AEs Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General AEs Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local AEs Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local AEs Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
        <time_frame>During the 4-day (Days 0-3) post-vaccination period following each primary dose</time_frame>
        <population>The analysis was performed on The Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
          <population>The analysis was performed on The Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
        <time_frame>During the 4-day (Days 0-3) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 4-day (Days 0-3) post-vaccination period following each primary dose</time_frame>
        <population>The analysis was performed on The Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on The Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever Dose 1 (N=90,94,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever Dose 2 (N=87,90,90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 4-day (Days 0-3) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever (defined as axillary temperature ≥ 37.5°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (axillary temperature) above (&gt;) 39.5 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Symptoms (Solicited and Unsolicited)</title>
        <description>The number of subjects with any and grade 3 symptoms (solicited and unsolicited), during the 31-day post-booster vaccination period is reported.</description>
        <time_frame>During the 31-day (Days 0-30) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Symptoms (Solicited and Unsolicited)</title>
          <description>The number of subjects with any and grade 3 symptoms (solicited and unsolicited), during the 31-day post-booster vaccination period is reported.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any symptom (N=86,87,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 symptom (N=86,87,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General symptom (N=86,87,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 general symptom (N=86,87,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local symptom (N=86,87,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 local symptom (N=86,87,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs</title>
        <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) post-primary vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs</title>
          <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs</title>
        <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs</title>
          <description>An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Booster Epoch, which included all subjects with booster vaccine administration documented and the symptom sheet filled in.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From first vaccination (Month 0) up to study end (11-14 months)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort for Primary Epoch, which included all subjects with at least one primary vaccine dose administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Serotypes</title>
        <description>Antibodies assessed for this outcome measure were those against the vaccine/cross-reactive pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (ANTI-1, -3, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F). Antibody concentrations were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL.</description>
        <time_frame>At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity adapted for each epoch, which included included all evaluable subjects for whom data concerning primary or booster immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Serotypes</title>
          <description>Antibodies assessed for this outcome measure were those against the vaccine/cross-reactive pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (ANTI-1, -3, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F). Antibody concentrations were measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity adapted for each epoch, which included included all evaluable subjects for whom data concerning primary or booster immunogenicity outcome measures were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1 Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.32" upper_limit="3.24"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.63" upper_limit="3.7"/>
                    <measurement group_id="O3" value="4" lower_limit="3.44" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1 Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.29" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.44" upper_limit="0.64"/>
                    <measurement group_id="O3" value="0.62" lower_limit="0.52" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1 Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" lower_limit="3.93" upper_limit="5.41"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.6" upper_limit="4.9"/>
                    <measurement group_id="O3" value="5.22" lower_limit="4.52" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-3 Month 3 (N=85,86,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.73" upper_limit="0.97"/>
                    <measurement group_id="O3" value="2.48" lower_limit="2.21" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-3 Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.07" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.18" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.3" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-3 Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.07" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.18" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.27" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" lower_limit="3.12" upper_limit="4.02"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.22" upper_limit="3.34"/>
                    <measurement group_id="O3" value="2.74" lower_limit="2.34" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 Month 10 (N=85,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.49" upper_limit="0.66"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.46" upper_limit="0.68"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.32" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" lower_limit="5.87" upper_limit="7.79"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.94" upper_limit="5.6"/>
                    <measurement group_id="O3" value="8.77" lower_limit="7.26" upper_limit="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" lower_limit="3.95" upper_limit="5.24"/>
                    <measurement group_id="O2" value="2.59" lower_limit="2.1" upper_limit="3.18"/>
                    <measurement group_id="O3" value="4.89" lower_limit="4.11" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 Month 10 (N=85,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.79" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.64" upper_limit="0.92"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.88" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5 Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" lower_limit="7.08" upper_limit="9.77"/>
                    <measurement group_id="O2" value="5.27" lower_limit="4.33" upper_limit="6.41"/>
                    <measurement group_id="O3" value="6.15" lower_limit="5.17" upper_limit="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A Month 3 (N=84,85,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.16" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.3" upper_limit="0.45"/>
                    <measurement group_id="O3" value="3.35" lower_limit="2.53" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A Month 10 (N=85,84,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.2" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.22" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.67" lower_limit="0.55" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.98" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.69" upper_limit="1.24"/>
                    <measurement group_id="O3" value="1.97" lower_limit="1.52" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Month 3 (N=86,88,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.78" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.17" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.29" upper_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.39" upper_limit="0.59"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.23" upper_limit="0.37"/>
                    <measurement group_id="O3" value="0.24" lower_limit="0.19" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.96" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.92" lower_limit="1.53" upper_limit="2.42"/>
                    <measurement group_id="O3" value="3.03" lower_limit="2.56" upper_limit="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F Month 3 (N=86,88,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="2.96" upper_limit="3.81"/>
                    <measurement group_id="O2" value="2.74" lower_limit="2.35" upper_limit="3.19"/>
                    <measurement group_id="O3" value="4.83" lower_limit="4.32" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F Month 10 (N=85,85,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.99" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1" lower_limit="0.84" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.24" lower_limit="1.07" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" lower_limit="6.69" upper_limit="8.71"/>
                    <measurement group_id="O2" value="5.07" lower_limit="4.38" upper_limit="5.87"/>
                    <measurement group_id="O3" value="5.83" lower_limit="5.07" upper_limit="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Month 3 (N=85,87,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="2.28" upper_limit="3.13"/>
                    <measurement group_id="O2" value="1.34" lower_limit="1.12" upper_limit="1.59"/>
                    <measurement group_id="O3" value="2.96" lower_limit="2.49" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.7" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.42" upper_limit="0.56"/>
                    <measurement group_id="O3" value="0.53" lower_limit="0.45" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04" lower_limit="5.99" upper_limit="8.26"/>
                    <measurement group_id="O2" value="2.48" lower_limit="2.11" upper_limit="2.92"/>
                    <measurement group_id="O3" value="2.84" lower_limit="2.42" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="3.87" upper_limit="5.81"/>
                    <measurement group_id="O2" value="3.45" lower_limit="2.79" upper_limit="4.25"/>
                    <measurement group_id="O3" value="4.99" lower_limit="3.89" upper_limit="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="0.89" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.86" upper_limit="1.29"/>
                    <measurement group_id="O3" value="1.78" lower_limit="1.45" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.04" lower_limit="8.44" upper_limit="11.95"/>
                    <measurement group_id="O2" value="8.1" lower_limit="6.68" upper_limit="9.83"/>
                    <measurement group_id="O3" value="7.62" lower_limit="6.3" upper_limit="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.54" upper_limit="4.28"/>
                    <measurement group_id="O2" value="3.22" lower_limit="2.5" upper_limit="4.14"/>
                    <measurement group_id="O3" value="3.24" lower_limit="2.62" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Month 10 (N=86,86,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.67" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.53" upper_limit="0.81"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.47" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.18" lower_limit="20.92" upper_limit="30.31"/>
                    <measurement group_id="O2" value="19.39" lower_limit="15.36" upper_limit="24.48"/>
                    <measurement group_id="O3" value="19.27" lower_limit="15.57" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.18" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.72" lower_limit="0.6" upper_limit="0.87"/>
                    <measurement group_id="O3" value="2.43" lower_limit="1.91" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.15" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.27" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.34" lower_limit="0.25" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="1.2" upper_limit="2.23"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.17" upper_limit="2.38"/>
                    <measurement group_id="O3" value="2.17" lower_limit="1.64" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Month 3 (N=86,89,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="3.76" upper_limit="5.69"/>
                    <measurement group_id="O2" value="5.67" lower_limit="4.63" upper_limit="6.95"/>
                    <measurement group_id="O3" value="4.17" lower_limit="3.69" upper_limit="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.96" upper_limit="1.48"/>
                    <measurement group_id="O2" value="1.39" lower_limit="1.14" upper_limit="1.71"/>
                    <measurement group_id="O3" value="0.53" lower_limit="0.43" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.43" lower_limit="12.02" upper_limit="17.32"/>
                    <measurement group_id="O2" value="13.57" lower_limit="11.29" upper_limit="16.32"/>
                    <measurement group_id="O3" value="13.81" lower_limit="11.63" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Month 3 (N=86,88,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.11" upper_limit="1.85"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.41" upper_limit="0.68"/>
                    <measurement group_id="O3" value="1.74" lower_limit="1.28" upper_limit="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Month 10 (N=86,86,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.41" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.19" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.36" lower_limit="0.29" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Month 11 (N=84,82,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" lower_limit="3.23" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.42" upper_limit="2.18"/>
                    <measurement group_id="O3" value="2.76" lower_limit="2.29" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Antibodies Against Protein D (Anti-PD)</title>
        <description>Anti-PD antibody concentrations were measured by Enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL). The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 153 EL.U/mL.</description>
        <time_frame>At study Month 3 (one month after primary vaccination) and at study Month 11 (one month after booster vaccination)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity adapted for each epoch, which included all evaluable subjects for whom data concerning primary or booster immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevnar 1 Group</title>
            <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Prevnar 2 Group</title>
            <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Antibodies Against Protein D (Anti-PD)</title>
          <description>Anti-PD antibody concentrations were measured by Enzyme-linked Immunosorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL). The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 153 EL.U/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity adapted for each epoch, which included all evaluable subjects for whom data concerning primary or booster immunogenicity outcome measures were available.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD Month 3 (N=45,50,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2025.1" lower_limit="1601" upper_limit="2561.4"/>
                    <measurement group_id="O2" value="117.2" lower_limit="90.4" upper_limit="152.1"/>
                    <measurement group_id="O3" value="143.2" lower_limit="106.8" upper_limit="192.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD Month 11 (N=45,42,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3658.5" lower_limit="2741.1" upper_limit="4882.8"/>
                    <measurement group_id="O2" value="791" lower_limit="576.2" upper_limit="1085.8"/>
                    <measurement group_id="O3" value="219.7" lower_limit="156.2" upper_limit="309.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 4-day post primary and booster vaccination period; Unsolicited AEs: during the 31-day post primary and booster vaccination period; SAEs: from first vaccination (Month 0) up to study end (11-14 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Group</title>
          <description>Subjects who were primed with two doses of Synflorix™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Prevnar 1 Group</title>
          <description>Subjects who were primed with Prevnar 13™ and Synflorix™ vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Prevnar 2 Group</title>
          <description>Subjects who were primed with two doses of Prevnar 13™ vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix™ vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Redness (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Swelling (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Redness (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Swelling (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Drowsiness (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Irritability (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Loss of appetite (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fever (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Drowsiness (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Irritability (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Loss of appetite (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Fever (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis (primary phase)</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis (booster phase)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

